Overexpression of cellular prion protein (PrP(C)) prevents cognitive dysfunction and apoptotic neuronal cell death induced by amyloid-ß (Aß1₋40) administration in mice.

The cellular prion protein (PrP(C)) is a neuronal-anchored glycoprotein that has been associated with several functions in the CNS such as synaptic plasticity, learning and memory and neuroprotection. There is great interest in understanding the role of PrP(C) in the deleterious effects induced by the central accumulation of amyloid-ß (Aß) peptides, a pathological hallmark of Alzheimer's disease, but the existent results are still controversial. Here we compared the effects of a single intracerebroventricular (i.c.v.) injection of aggregated Aß(1-40) peptide (400pmol/mouse) on the spatial learning and memory performance as well as hippocampal cell death biomarkers in adult wild type (Prnp(+/+)), PrP(C) knockout (Prnp(0/0)) and the PrP(C) overexpressing Tg-20 mice. Tg-20 mice, which present a fivefold increase in PrP(C) expression in comparison to wild type mice, were resistant to the Aß(1-40)-induced spatial learning and memory impairments as indicated by reduced escape latencies to find the platform and higher percentage of time spent in the correct quadrant during training and probe test sessions of the water maze task. The protection against Aß(1-40)-induced cognitive impairments observed in Tg-20 mice was accompanied by a significant decrease in the hippocampal expression of the activated caspase-3 protein and Bax/Bcl-2 ratio as well as reduced hippocampal cell damage assessed by MTT and propidium iodide incorporation assays. These findings indicate that the overexpression of PrP(C) prevents Aß(1-40)-induced spatial learning and memory deficits in mice and that this response is mediated, at least in part, by the modulation of programed cell death pathways.

Role of ventral hippocampal nitric oxide/cGMP pathway in anxiety-related behaviors in rats submitted to the elevated T-maze.

The L-arginine/nitric oxide (NO)/cGMP pathways have been implicated in the control of a variety of physiological mechanisms and are believed to participate in the modulation of anxiety in the CNS. The aim of this study was to investigate the effects of N(G)-nitro-L-arginine-methyl-ester (L-NAME), a non-selective inhibitor of NO synthase (NOS); 7-nitroindazole (7-NI), a preferential inhibitor of neuronal NOS; and sodium nitroprusside (SNP), an NO donor, administered into the ventral hippocampus (VH) of rats submitted to the elevated T-maze (ETM). The ETM, an animal model derived from the elevated plus-maze, allows the measurement of two defensive behavioral responses in the same rat: inhibitory avoidance and escape. Results showed that L-NAME and 7-NI impaired the acquisition of inhibitory avoidance and prolonged escape latency in the ETM, suggesting an anxiolytic-like and panicolytic-like effect, respectively. SNP facilitated the acquisition of inhibitory avoidance without interfering with escape performance, suggesting an anxiogenic-like effect. Treatment with methylene blue did not alter per se any of the behavioral responses measured in the ETM, but blocked the effect promoted by SNP. Thus, altogether these results suggest that NO in the VH is critically involved in the modulation of defensive behavior of rats exposed to the ETM.

Cellular prion protein modulates age-related behavioral and neurochemical alterations in mice.

The cellular prion protein (PrP(C)) is a neuronal-anchored glycoprotein that has been associated with various functions in the CNS such as synaptic plasticity, cognitive processes and neuroprotection. Here we investigated age-related behavioral and neurochemical alterations in wild-type (Prnp(+/+)), PrP(C) knockout (Prnp(0/0)) and the PrP(C) overexpressing Tg-20 mice. Three- or 11 month-old animals were submitted to a battery of behavioral tasks including open field, activity cages, elevated plus-maze, social recognition and inhibitory avoidance tasks. The 11 month-old Prnp(+/+) and Prnp(0/0) mice exhibited significant impairments in their locomotor activity and social recognition memory and increased anxiety-related responses. Remarkably, Tg-20 mice did not present these age-related impairments. The i.c.v. infusion of STI1 peptide 230-245, which includes the PrP(C) binding site, improved the age-related social recognition deficits in Prnp(+/+). In comparison with the two other age-matched genotypes, the 11 month-old Tg-20 mice also exhibited reduced activity of seric acetylcholinesterase, increased expression of the protein synaptophysin and decreased caspase-3 positive-cells in the hippocampus. The present findings obtained with genetic and pharmacological approaches provide convincing evidence that PrP(C) exerts a critical role in the age-related behavioral deficits in mice probably through adaptive mechanisms including apoptotic pathways and synaptic plasticity.

Nitric oxide involvement and neural substrates of the conditioned and innate fear as evaluated in the T-maze test in rats.

The L-arginine/nitric oxide (NO) pathways are widely distributed in the central nervous system (CNS) and have been implicated in the modulation of anxiety. The elevated plus-maze (ETM) is an animal test pharmacologically validated for the study of experimental anxiety in rats, designed to evaluate inhibitory avoidance (AVOID) learning and one-way escape (ESC) from open arms, thought to represent learned (conditioned) and innate (unconditioned) fear, respectively. The aim of the present study was to evaluate the effect of prior treatment with the NO-synthase inhibitor N omega-nitro-L-arginine methyl ester (L-NAME) on both AVOID and ESC behavior of rats in the ETM, when applied to different cerebral regions associated with defensive behaviors. Central treatment with L-NAME (50, 100, 400 and 800 nmol) did not impair the AVOID response through the trials and had no effect on the ESC behavior. Nevertheless, animals treated with L-NAME at 200 nmol into the lateral ventricle (LV), basolateral amygdala (BLA), dorsolateral periaqueductal gray (dlPAG) matter, lateral septal nucleus (LSN), but not in the bed nucleus of stria terminalis (BNST), displayed impaired AVOID2 in comparison to the control group. Thus, our results suggest that NO may underlie learned fear in the ETM via BLA, dlPAG and LSN, but not BNST. These results are compatible with the proposal that NO exerts a positive modulatory role on defensive reactions in rats, exerting among them an anxiogenic-like effect as evaluated in rats submitted to ETM.

Genetic deletion or antagonism of kinin B(1) and B(2) receptors improves cognitive deficits in a mouse model of Alzheimer's disease.

Increased brain deposition of amyloid beta protein (Abeta) and cognitive deficits are classical signs of Alzheimer's disease (AD) that have been widely associated to inflammatory response. We have recently shown that a single i.c.v. injection of aggregated beta-amyloid peptide-(1-40) (Abeta(1-40)) (400 pmol/mouse) results in marked deficits of learning and memory in mice which are related to oxidative stress and synaptic dysfunction. In the present study, we investigated by means of genetic or pharmacological approaches the role of kinin system in the Abeta(1-40) cognitive effects on the water maze paradigm. Spatial learning and memory deficits observed at 7 days following Abeta(1-40) treatment were significantly reduced by the i.c.v. administration of the selective kinin B(2) receptor antagonist d-Arg-[Hyp(3),Thi(5),D-Tic(7),Oic(8)]-BK (Hoe 140). A similar effect was found in mice lacking kinin B(2) receptor. On the other hand, genetic deletion of the inducible kinin B(1) receptor or its blockage by i.c.v. injection of des-Arg(9)-[Leu(8)]-BK antagonist attenuated only the long-term (30 days after treatment) cognitive deficits induced by Abeta(1-40). Moreover, treatment with Abeta(1-40) resulted in a sustained increase in the expression of the kinin B(1) receptor in the hippocampus and prefrontal cortex of mice, while it did not alter the expression of the kinin B(2) receptor in these brain areas. These findings provide convincing evidence that kinins acting via activation of B(1) and B(2) receptors in the CNS exert a critical role in the spatial learning and memory deficits induced by Abeta peptide in mice. Therefore, selective kinin receptor antagonists, especially the new orally active non-peptide antagonists, might represent drugs of potential interest for the treatment of AD.